CClinicalTrials.gg
CompletedNCT03876795INTERFACEUpdated Apr 19, 2023

Evaluation of Effectiveness of Combined Intra-articular and Intra-osseus Injection VS a Single Intra-articular Injection of Bone Marrow Concentrate

A Phase 3 interventional study of Bone Marrow Concentrate in Osteoarthritis, Knee, sponsored by Istituto Ortopedico Rizzoli. Completed at 1 site in Italy. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-04-19.

Sponsored by Istituto Ortopedico Rizzoli · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

Osteoarthritis (OA) is one of the most common diseases resulting in large burdens on society.

Among the emerging treatments, Bone Marrow Concentrate (BMC) intra-articular injections are a promising regenerative approach. However, they offer only a temporary benefit since they target synovial and chondral tissues but fail to address the osteochondral interface, which plays a key role in the onset and progression of joint degeneration.

This project will investigate the efficacy of combined BMC injections, targeting both intra-articular tissues and subchondral bone, to treat OA in a Randomized Controlled Trial (RCT).

Read the detailed description

The main aim is to evaluate in a RCT the potential of a new combined BMC treatment for OA, through the use of scores for the clinical outcome, the study of imaging and biological samples for tissue regeneration and systemic effects, and the identification of BMC and patient characteristics predictive of better results.

All patients will undergo an arthroscopic procedure to debride degenerated tissues (this can offer a temporary benefit but not long lasting results) before BMC intra-articular injection. Half patients will receive also the injection of BMC at the subchondral level (bone samples obtained to allow BMC placement will be sent to the Lab).

The same minimally invasive incisions will be used for all patients, ensuring patient blinding. Evaluations, performed by medical staff not involved in the treatment to ensure double blinding, will document subjective clinical improvement, functional measurements, biomarker study, and imaging with the use of modern 3TMRI and qCT technology. BMC characterization and patient features will be analysed to identify factors predictive of a better outcome.

02

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • Bone Marrow Comcentrate
  • intra-articular
  • intra-osseus
03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 86 is above the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Istituto Ortopedico Rizzoli is the lead sponsor of 298 studies on the registry; 102 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male or female patients, aged between 40 and 70;
  2. Arthrosis of the medial compartment (grade 2-3 according to the Kellgren-Lawrence score> 4 months);
  3. Failure after at least 6 months of conservative treatment (drug therapy with NSAIDs and painkillers, hyaluronic acid infiltration, corticosteroid infiltration, PRP);
  4. Patients' ability and consent to participate in clinical and radiological follow-up;
  5. Signature of informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Patients with trauma in the 6 months prior to surgery;
  2. Patients with maligncy;
  3. Patients suffering from rheumatic diseases;
  4. Patients suffering from non-compensated diabetes;
  5. Patients suffering from uncompensated thyroid metabolic disorders;
  6. Patients abusing alcoholic beverages, drugs or drugs;
  7. Patients with axial deviations> 5 °;
  8. Body Mass Index> 35;
  9. Patients treated with joint infiltrations in the previous 6 months;
  10. Patients treated with surgery at the same knee in the previous 12 months.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Active comparator
    Single intra-articular Bone Marrow Concentrate injection

    Single intra-articular Bone Marrow Concentrate injection in the knee

    Biological: Bone Marrow Concentrate

  • Experimental
    combined Bone Marrow Concentrate injection

    combined Bone Marrow Concentrate injection (intra-articular and intra-osseus)

    Biological: Bone Marrow Concentrate

Interventions

  • BiologicalBone Marrow Concentrate

    Bone Marrow Concentrate injection

06

What researchers measure

Primary outcomes

  1. change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score trend over time

    WOMAC is a validated score, designed to highlight the problems of patients with lower limb pathologies, in particular in terms of pain, stiffness and functionality. The score will be completed by the patient, possibly in the presence of an investigator, and simple guidelines for self-compilation will be provided.

    Time frame: basal 2,6,12 months after treatment

Secondary outcomes

  1. IKDC Subjective Knee Evaluation Form (IKDC)

    IKDC is a validated score used in the evaluation of symptoms, function and sport activity in patients suffering of knee diseases, such as meniscal or ligamentous damage, osteoarthritis. The Subjective Knee Form provides the best method of overall assessment of the most significant symptoms and disabilities for a population that has undergone cartilage repair treatments.

    Time frame: 2,6,12 months

07

Study locations

1 site
  • Rizzoli Orthopaedic Institute
    Bologna, 40136, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03876795
Lead sponsor
Istituto Ortopedico Rizzoli
Responsible party
Sponsor
First posted
Mar 15, 2019
Start date
Nov 8, 2019
Primary completion
Mar 1, 2023
Completion
Mar 1, 2023
Last update
Apr 19, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion